This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
by Zacks Equity Research
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
by Ekta Bagri
NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.
CRISPR Therapeutics Stock Falls 34% in a Year: Time to Buy or Sell?
by Sundeep Ganoria
The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed product in early 2024, CRSP is yet to record product sales.
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
by Zacks Equity Research
Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
by Zacks Equity Research
MRNA and NTLA are down this week after providing financial and strategic updates.
NTLA Announces Strategic Reorganization & Job Cuts in 2025, Stock Down
by Zacks Equity Research
Intellia Therapeutics stock falls after the company announces key milestones for 2025. It plans to reduce the current workforce by 27%.
Intellia Crashes 60% in a Year: How Should You Play the Stock?
by Ekta Bagri
NTLA stock is down significantly in 2024 as investors are not pleased with the recent data from its in vivo CRISPR-based therapies. We advise prospective investors to stay on the sidelines for now.
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
by Zacks Equity Research
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy
by Zacks Equity Research
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating hereditary transthyretin (ATTR) amyloidosis with polyneuropathy.
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Intellia's third-quarter earnings and revenues surpass estimates. The company provides updates on its pipeline candidates.
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 2.19% and 7.73%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NTLA Begins Phase III Study on Hereditary Angioedema Candidate
by Zacks Equity Research
Intellia starts the pivotal phase III HAELO study on NTLA-2002 for the treatment of hereditary angioedema (HAE).
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of -8.26% and 65.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Intellia's (NTLA) second-quarter 2024 earnings call, investors' focus is likely to be on the progress of its pipeline of genome-editing candidates.
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
by Zacks Equity Research
The FDA grants the Regenerative Medicine Advanced Therapy ("RMAT") designation to Kyvernas' (KYTX) lead candidate, KYV-101, for the treatment of patients suffering from refractory stiff-person syndrome.
All You Need to Know About Intellia Therapeutics (NTLA) Rating Upgrade to Strong Buy
by Zacks Equity Research
Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down
by Zacks Equity Research
Intellia (NTLA) appoints Edward Dulac as its new chief financial officer after Glenn Goddard steps down from his role with effect from Jun 30.
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
by Zacks Equity Research
Intellia's (NTLA) lead genome-editing candidate, NTLA-2001 being developed to treat transthyretin (ATTR) amyloidosis, holds promise. Other pipeline candidates are also progressing well.
Intellia (NTLA) Up on Upbeat Long-Term Angioedema Study Data
by Zacks Equity Research
Intellia (NTLA) gains 10% after reporting encouraging long-term efficacy data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema.
Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Intellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates. Stock rises.